This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Catalog
ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.
Article
Parkinson’s disease and cancer: a systematic re and meta-analysis of over 17 million participants
Published: The authors examined risk association between Parkinson’s disease and cancer using data from 63 publications, totaling in 17 million individuals. With the exception of melanoma, the authors found that the risk association of Parkinson’s disease and cancer was inversely related.
Teams
Protocol
Post mortem human substantial nigra TH staining
This protocol is standardized for postmortem (frozen) SN tissue from pathologically diagnosed PD patients and control individuals for Immunofluorescence staining.
Teams
Protocol
Unilateral intranigral AAV alpha synuclein mouse model
This protocol details methods for the unilateral intranigral AAV alpha-synuclein injection.
Teams
Protocol
Striatal dopamine measurement through HPLC
Protocol for striatal dopamine measurement in mouse brain
Teams
Article
DOPA pheomelanin is increased in neuromelanin of Parkinson’s disease substantia nigra and it exacerbates alpha-synuclein neurotoxicity
Preprint: Neuromelanin in the substantia nigra may be a key factor contributing to dopaminergic neuron vulnerability in Parkinson’s disease. Neuromelanin consists of pheomelanin and eumelanin moieties. Here, the authors investigated the relative composition and specific roles of pheomelanin and eumelanin moieties of NM in PD.
Teams